期刊文献+

基于术前MRI特征及定量参数列线图预测乳腺癌患者淋巴血管侵犯

Nomogram for predicting lymphovascular invasion in breast cancer using MRI features and quantitative parameters
下载PDF
导出
摘要 目的开发基于术前磁共振成像(magnetic resonance imaging,MRI)特征及表观扩散系数(apparent diffusion coefficient,ADC)的列线图预测浸润性乳腺癌淋巴血管侵犯(lymphovascular invasion,LVI)。材料与方法回顾性分析141例浸润性乳腺癌患者资料,其中2019年3月至2021年7月的66例患者作为训练组,2021年7月至2022年12月的75例患者作为验证组。评估病灶MRI特征(肿块形状、边缘、内部强化形式、瘤周水肿等)及测量ADC。采用卡方检验、独立样本t检验及Mann-Whitney U检验分析LVI阳性组和LVI阴性组间影像学特征和瘤内、瘤周ADC平均值、最大值及最小值的差异。采用多因素逻辑回归分析确定与LVI相关的独立危险因素,建立预测LVI的列线图模型。结果LVI阳性组和LVI阴性组间在肿瘤大小、Ki-67表达以及淋巴结转移率方面的差异具有统计学意义(P<0.05)。多因素逻辑回归分析显示,肿块形态[P=0.014,优势比(odds ratio,OR)=0.142(0.030~0.679)]、内部强化形式[P=0.046,OR=0.157(0.025~0.965)]、肿瘤最大径[P=0.037,OR=4.372(1.093~17.488)]、扩散加权成像(diffusion-weighted image,DWI)边缘征[P=0.024,OR=0.193(0.047~0.803)]及瘤周瘤内ADC比值[P=0.010,OR=1.056(1.013~1.101)]是LVI的独立预测因素。基于MRI特征和瘤周瘤内ADC比值的综合预测模型在训练组及验证组中的受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)分别为0.867、0.872,特异度分别为88.6%、84.6%,精确度分别为74.2%、69.7%。校准曲线表明,列线图在训练组和验证组中预测值与实际值吻合较好。结论基于术前MRI影像特征及ADC的列线图评估乳腺癌LVI状态具有较高的预测效能,有助于临床在指导手术、制订个性化治疗方案及评估预后等方面的决策。 Objective:To develop a nomogram based on preoperative magnetic resonance imaging(MRI)features and apparent diffusion coefficient(ADC)to predict lymphovascular invasion(LVI)in invasive breast cancer.Materials and Methods:A retrospective analysis was conducted on data from 141 patients with invasive breast cancer.Among them,66 patients from March 2019 to July 2021 were assigned to the training group,and 75 patients from July 2021 to December 2022 were assigned to the validation group.The evaluation included assessment of lesion MRI features(such as mass shape,margins,internal enhancement patterns,and peritumoral edema)and measurement of ADC.The differences in imaging features and mean,maximum,and minimum ADC values within the tumor and peritumoral regions between the LVI-positive and LVI-negative groups were analyzed using chi-square tests,independent sample t-tests,and Mann-Whitney U tests.Multivariate logistic regression analysis was employed to identify independent risk factors associated with LVI and to establish a nomogram model for predicting LVI.Results:LVI was significantly associated with tumor size,Ki-67 expression,and lymph node metastasis rate.Multivariable logistic regression analysis showed that tumor shape[P=0.014,odds ratio(OR):0.142(0.030-0.679)],internal enhancement patterns[P=0.046,OR:0.157(0.025-0.965)],maximum tumor diameter[P=0.037,OR:4.372(1.093-17.488)],DWI rim[P=0.024,OR:0.193(0.047-0.803)],and ADCration[P=0.010,OR:1.056(1.013-1.101)]were independent predictors of LVI.Areas under the receiver operating characteristic curve of the comprehensive prediction model based on MRI features and peritumoral intratumoral ADC ratio in the training and validation groups were 0.867 and 0.872,the specificity were 88.6%and 84.6%,and the precision were 74.2%and 69.7%,respectively.Calibration curves demonstrated good agreement between predicted and actual values in the training and validation groups.Conclusions:LVI is correlated with various clinical and pathological prognostic factors and MRI imaging features.The comprehensive model based on preoperative MRI features and apparent diffusion coefficient demonstrates good predictive efficiency for LVI,that contribute to clinical decision-making in guiding surgery,developing individualized treatment plans,and assessing prognosis.
作者 程思佳 翟晓阳 周仕豪 毛珂 危涵羽 韩东明 CHENG Sijia;ZHAI Xiaoyang;ZHOU Shihao;MAO Ke;WEI Hanyu;HAN Dongming(Department of MRI,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)
出处 《磁共振成像》 CAS CSCD 北大核心 2024年第5期111-118,共8页 Chinese Journal of Magnetic Resonance Imaging
基金 北京康盟慈善基金会医学科研发展基金项目(编号:B21145AN)。
关键词 乳腺肿瘤 浸润性乳腺癌 淋巴血管侵犯 瘤周组织 列线图 磁共振成像 表观扩散系数 breast tumor invasive breast cancer lymphovascular invasion peritumoral area nomogram magnetic resonance imaging apparent diffusion coefficient
  • 相关文献

参考文献4

二级参考文献33

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 4Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 5Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 6Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 7Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 8Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 9Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 10Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.

共引文献454

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部